SUN Pharmaceutical Industries
- ISIN
- INE044A01036
- Instrument key
- NSE_EQ|INE044A01036
as of 21/11/2026, 2:30:13 pm
- Open
- ₹1,898.00
- Day high
- ₹1,910.00
- Day low
- ₹1,883.00
- Prev. close
- ₹1,900.00
- Volume
- 19.16 L
- VWAP
- ₹1,892.13
02/Price history
Price chart
1 day · 5-minute candles. Hover the chart for the OHLC of any candle; the table below holds the same data row by row.
No candles for this range
Intraday candles are empty outside market hours — pick a longer range.
Candle data0 rows of open, high, low, close and volumeShowHide
No candles in this range
03/Valuation & returns
Key ratios vs sector
Company value benchmarked against the sector median. The ratio set is sector specific — banks report NIM, CASA and Net NPA instead of EV/EBITDA.
Price ÷ earnings per share
Worse than sector by 191%
Price ÷ book value per share
Worse than sector by 20%
Net income ÷ total assets
Better than sector by 708%
Net income ÷ shareholders' equity
Better than sector by 3547%
EBIT ÷ capital employed
Better than sector by 21%
Liquid assets ÷ current liabilities
Worse than sector by 52%
Enterprise value ÷ EBITDA
Worse than sector by 4%
04/Business
About the company
Sector: Pharmaceuticals
Sun Pharmaceutical Industries Limited is an India-based specialty generic pharmaceutical company with a presence in specialty, generics and consumer healthcare products. The Company's global specialty portfolio spans products in dermatology, ophthalmology, and onco-dermatologym, among others. The Company manufactures and markets a large basket of pharmaceutical formulations across chronic and acute therapies, including generic, branded generics, specialty and complex products, over-the-counter (OTC), antiretrovirals (ARV), Active Pharmaceutical Ingredients (API), and intermediates. Its portfolio spans multiple dosage forms, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids. Its marketed specialty portfolio includes Ilumya/ Ilumetri, Winlevi, Levulan Kerastick + BLU-U, Absorica LD, Odomzo, Cequa, Bromsite, Xelpros, and others. Its portfolio also includes UNLOXCYTTM, an anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma.
- ₹4,52,299 Cr
- $50.26B
reported in crore
reported in billion
Market capitalisation is reported at the sector-constituent level, not the standalone company level.
05/Profit & loss
Standalone income statement
Annual figures in ₹ crore. Growth marked reported is provided; margins are derived.
- Revenue · Mar 2026
- ₹21,174 Cr-9.34% vs Mar 2025
- Net profit · Mar 2026
- ₹2,623 Cr-37.95% vs Mar 2025
- Operating margin
- 17.9%was 21.3%
- Revenue CAGR · 4p
- 0.1%profit 15.8% · op 29.6%
| Revenue | 21,174 | 23,357 | 20,741 | 21,091 |
|---|---|---|---|---|
| Revenue growthreported | -9.3% | 12.6% | -1.7% | — |
| Operating profit | 3,794 | 4,976 | 3,450 | 1,741 |
| Operating profit growthreported | -23.8% | 44.3% | 98.1% | — |
| Operating marginderived | 17.9% | 21.3% | 16.6% | 8.3% |
| Net profit | 2,623 | 4,228 | 2,858 | 1,691 |
| Net profit growthreported | -38.0% | 47.9% | 69.0% | — |
| Net marginderived | 12.4% | 18.1% | 13.8% | 8.0% |
| EPS — basic₹/share, annual | 10.90 | 17.60 | 11.90 | 7.00 |
Figures in ₹ crore. Margin rows are computed from the reported values.
Full annual line itemsRevenue, other income, expenses, tax, EPSShowHide
| Revenue | 20,755 | 22,977 | 20,275 | 20,812 |
|---|---|---|---|---|
| Other Income | 1,776 | 634 | 553 | 329 |
| Total Revenue | 22,531 | 23,612 | 20,829 | 21,141 |
| Total Expenses | 18,191 | 18,636 | 17,160 | 16,463 |
| Profit Before Tax | 3,794 | 4,976 | 3,450 | 1,741 |
| Tax | 1,171 | 748 | 591 | 50 |
| Profit After Tax | 2,623 | 4,228 | 2,858 | 1,691 |
| EPS - Basic | 10.90 | 17.60 | 11.90 | 7.00 |
| EPS - Diluted | 10.90 | 17.60 | 11.90 | 7.00 |
This breakdown is available annually, even when the summary above is quarterly. EPS rows are per share.
06/Balance sheet
Standalone balance sheet
Only annual balance sheets are available — the quarterly filter does not apply here. Figures in ₹ crore; net worth is assets minus liabilities.
- Total assets · Mar 2026
- ₹43,060 Cr-1.87% YoY
- Total liabilities
- ₹20,689 Cr
- Net worth
- ₹22,371 Cr
- Liabilities ÷ assets
- 48.0%lower means a lighter balance sheet
| Total assets | 43,060 | 43,878 | 41,065 | 40,987 |
|---|---|---|---|---|
| Total liabilities | 20,689 | 19,978 | 17,370 | 17,239 |
| Net worthderived | 22,371 | 23,900 | 23,694 | 23,748 |
| Liabilities ÷ assetsderived | 48.0% | 45.5% | 42.3% | 42.1% |
| Asset growthderived | -1.9% | 6.9% | 0.2% | — |
Figures in ₹ crore. Stacked chart height equals total assets.
Full annual line itemsNon-current & current assets, liabilities, equity capitalShowHide
| Non-Current Assets | 26,381 | 25,098 | 26,152 | 24,544 |
|---|---|---|---|---|
| Current Assets | 16,679 | 18,781 | 14,913 | 16,444 |
| Total Assets | 43,060 | 43,878 | 41,065 | 40,987 |
| Current Liabilities | 6,503 | 18,202 | 4,445 | 8,365 |
| Net Current Asset | 10,175 | 578 | 10,468 | 8,078 |
| Non-Current Liabilities | 14,186 | 1,776 | 12,926 | 8,874 |
| Equity Capital | 22,371 | 23,900 | 23,694 | 23,748 |
| Total Equity & Liabilities | 43,060 | 43,878 | 41,065 | 40,987 |
Figures in ₹ crore unless the line item is per-share.
07/Cash flow
Standalone cash flow
Annual only, in ₹ crore. Negative values are outflows, so healthy companies usually show positive operating and negative investing cash flow.
- Operating · Mar 2026
- ₹6,501 Cr+52.89% YoY
- Investing
- -₹1,381 Cr
- Financing
- -₹5,230 Cr
- Free cash flow
- ₹5,120 Croperating + investing
| Operating activities | 6,501 | 4,252 | -292 | 507 |
|---|---|---|---|---|
| Operating changereported | 52.9% | 1554.1% | -157.7% | — |
| Investing activities | -1,381 | -258 | -263 | -705 |
| Investing changereported | -434.9% | 1.8% | 62.7% | — |
| Financing activities | -5,230 | -3,836 | 474 | 169 |
| Financing changereported | -36.3% | -909.4% | 179.9% | — |
| Net cash flowderived | -110 | 158 | -81 | -29 |
| Free cash flowoperating + investing | 5,120 | 3,994 | -555 | -198 |
Figures in ₹ crore.
Full annual line itemsProfit before tax through closing cash balanceShowHide
| Profit before tax | 3,794 | 4,976 | 3,450 | 1,741 |
|---|---|---|---|---|
| Income before WC changes | 5,258 | 6,760 | 5,219 | 6,564 |
| Change in Assets | 1,308 | -2,968 | -1,188 | -3,600 |
| Change in Liabilities | 336 | 594 | -3,981 | -2,025 |
| Change in WC | 1,643 | -2,374 | -5,169 | -5,625 |
| Cash flow from Operations | 6,501 | 4,252 | -292 | 507 |
| Cash flow from Investing | -1,381 | -258 | -263 | -705 |
| Cash flow from Financing | -5,230 | -3,836 | 474 | 169 |
| Total Cash Flow | -110 | 158 | -81 | -29 |
| Cash (Start of the year) | 493 | 327 | 410 | 420 |
| Cash (End of the year) | 418 | 493 | 326 | 410 |
Figures in ₹ crore unless the line item is per-share.
09/Events
Corporate actions
Dividends, bonuses, splits and rights issues. Filter by type, sort by any date, and expand a row for the full event detail.
| DividendFinal | ₹5.00 | 500.0% | 07 Jul 2026 | 07 Jul 2026 | 22 May 2026 | |
| DividendInterim | ₹11.00 | 1100.0% | 05 Feb 2026 | 05 Feb 2026 | 20 Jan 2026 |
10/Comparison
Peers & competitors
Competitor set priced live. Filter by sector, sort any column, and expand a peer for its business description.
| DIVISLABDivi S Laboratories Ltd | Pharmaceuticals | ₹11,180.50 | +0.02% | 4.05 L | ₹2,97,325 Cr | $33.04B | |
| TORNTPHARMTorrent Pharmaceuticals L | Pharmaceuticals | ₹4,689.50 | +1.70% | 2.00 L | ₹1,78,727 Cr | $19.86B | |
| LAURUSLABSLaurus Labs Limited | Pharmaceuticals | ₹2,294.60 | -0.49% | 8.79 L | ₹1,24,002 Cr | $13.78B | |
| ZYDUSLIFEZydus Lifesciences Ltd | Pharmaceuticals | ₹1,200.00 | -0.24% | 7.80 L | ₹1,19,207 Cr | $13.25B | |
| DRREDDYDR. Reddy S Laboratories | Pharmaceuticals | ₹1,390.20 | -0.76% | 8.31 L | ₹1,16,145 Cr | $12.90B | |
| CIPLACipla Ltd | Pharmaceuticals | ₹1,415.00 | -0.25% | 14.84 L | ₹1,14,312 Cr | $12.70B | |
| MANKINDMankind Pharma Limited | Pharmaceuticals | ₹2,665.00 | +1.37% | 4.56 L | ₹1,09,870 Cr | $12.21B | |
| AUROPHARMAAurobindo Pharma Ltd | Pharmaceuticals | ₹1,799.00 | -0.37% | 8.11 L | ₹1,03,298 Cr | $11.48B | |
| LUPINLupin Limited | Pharmaceuticals | ₹2,014.00 | +0.76% | 6.31 L | ₹91,916 Cr | $10.21B | |
| GLENMARKGlenmark Pharmaceuticals | Pharmaceuticals | ₹2,648.00 | +1.51% | 5.40 L | ₹74,733 Cr | $8.30B |
Market cap is the sector-constituent figure reported per peer · Showing 1–10 of 10
11/Coverage
Company news
Articles published in the last seven days, paginated by the provider.
No news in the last seven days
Company news is available for a rolling one-week window.